Navigation Links
Hard To Treat Diseases (HTDS) exclusive agent and partner of NCPC
Date:8/11/2009

SHENZHEN, China, Aug. 11 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), (http://www.htdsmedical.com) subsidiary, Shenzhen Mellow Hope Pharm Industrial Co., Ltd. (Mellow Hope) is pleased to announce that an agreement was reached between Mellow Hope and NCPC.

NCPC is the biggest modern Pharmaceutical manufacturer in China. http://www.ncpc.com.cn

In accordance with the agreement, Mellow Hope was appointed as the exclusive agent and partner of NCPC for its international marketing of Recombinant Hepatitis B Vaccine (CHO).

MARKET BACKGROUND

With the world's largest population and 17 million newborn babies each year, China is the world's fourth largest vaccine market. In China, vaccines represent a market worth over 3 billion RMB ($3.88 million), and this market is growing at 15% annually, reports Dr. Jianyuan Liu, associate director of National Vaccine and Serum Institute (NVSI) in the study, Advances in Biopharmaceutical Technology in China.1 Today, China has the largest vaccine manufacturing capabilities and capacity in the world. Dr. Liu and his colleagues also predict that China's vaccine market demand will rise to 20% in the next few years. Recent improvements in China's regulatory, market, and technology scenario are creating an optimistic outlook for its vaccine industry.

Large population, many newborns

China's population reached 1.3 billion in 2005 and will approach 1.4 billion in the next decade. The state has managed to control its birth rate to between 1.2% and 1.3%. Each year, approximately 17 million Chinese babies are born and all are suppose to receive vaccination. Based on this number, the following vaccine doses are needed each year for newborn babies:2

  Poliomyelitis vaccine 68 million doses   Diphtheria-pertussistetanus vaccine 68 million doses   Hepatitis B vaccine 51 million doses   Measles vaccine 34 million doses   BCG vaccine 17 million doses

The aforementioned statistics and data were obtained from the following sources without permission

   http://bioplanassociates.com (Direct link bellow)
   
http://bioplanassociates.com/publications/articles/VACCINES_China_Zhou_Apr07_C
hinaB.pdf

The HTDS management sees this agent agreement as a great potential boost of its revenue streams in introducing International marketing of Recombinant Hepatitis B Vaccine(CHO) to Mellow Hope's already existing distribution network.

In other company news, the company IP progress, Q2 financials and other corporate business matters are in the process of undergoing final review. These will be filed shortly and followed with an announcement.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Using coxibs and NSAIDs to treat osteoarthritis
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
5. Free distribution of insecticide-treated mosquito nets can save lives
6. Kenyan malaria success strengthens call for free insecticide-treated nets for all
7. Broad-based group of physicians calls for improvement in stroke treatment
8. Cranberry Could Juice Up Ovarian Cancer Treatment
9. Is 4 agents decoction (Si Wu Tang) efficacious in treating primary dysmenorrhea?
10. Non-medicinal treatment touted for pre-schoolers with ADHD
11. Nonmedicinal treatment touted for preschoolers with ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... ... March 23, 2017 , ... A recent report from the National Council on ... The NCTQ report suggests, based on a review of GPA and SAT/ACT requirements at ... in the U.S. It argues that this higher bar should be set by states, ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... their communities, 16 more public health departments have been awarded national accreditation through ... 4.5 million people into the expanding network of communities across the nation whose ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... City Convention Center at 10 North Broadway Avenue, will be an educational and ... relevant, practical instruction in the management of chronic pain. , Oklahoma is in ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition ... to their offering. ... The global oxygen therapy devices market to grow at a ... report, Global Oxygen Therapy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
(Date:3/23/2017)... 2017 A research report by Mordor ... to reach USD 7.2 billion by the end of 2021 ... a procedure in which a sample is preserved prior to ... procedures since the methods are often allowing repeated testing. The ... most shared procedures in the lab. In many life science ...
(Date:3/23/2017)... -- Newborns are highly vulnerable to infections and ... young immune systems typically mount weak antibody responses. ... strong vaccine responses in newborn animals, including monkeys ... — by adding compounds known as adjuvants that ... they also describe improved adjuvant formulations that could ...
Breaking Medicine Technology: